A Phase 1 interventional study of Cyclobenzaprine 10 Mg Oral Tablet and Placebo Oral Tablet in Driving Impaired, sponsored by Neurana Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-01.
Sponsored by Neurana Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized blinded study to assess the sedative effect of 150 mg TID tolperisone and 10 mg TID cyclobenzaprine compared to placebo on simulated driving performance and cognitive functioning in healthy adult volunteers.
This will be a randomized, placebo-controlled, multiple-dose 3-way cross-over study of the safety and cognitive effects of multiple doses of 150 mg tolperisone administered TID in 30 male and female healthy volunteers. Treatment groups include 450 mg tolperisone (i.e., 150 mg administered three times daily), 30 mg cyclobenzaprine (i.e., 10 mg administered three times daily), and placebo. Subjects will receive 3 days of each treatment.
Subject participation will be approximately 3 weeks as outpatients with 3 days each week as overnight clinic participants.
In this crossover study, treatment effects will be assessed following the second initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).
Subjects will be dosed on the morning of Day 1. Approximately one hour after the second dose on Day 1, subjects will be administered the cognitive test, followed by the driving simulator examination.
On the morning of Day 2, prior to dosing, subjects will be readministered the cognitive test and driving examination to assess residual next day effects.
Subjects will repeat cognitive testing and the driving examination on the morning of Day 3, after administration of the AM study medication, to evaluate the cumulative effects of 3 days of dosing.
Neurana Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects who have a history or diagnosis of any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days
Drug: Cyclobenzaprine 10 Mg Oral Tablet · Drug: Placebo Oral Tablet
sugar pills administered by mouth every 8 hours for 3 days
Drug: Cyclobenzaprine 10 Mg Oral Tablet · Drug: Placebo Oral Tablet
10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days
Drug: Placebo Oral Tablet
cyclobenzaprine 10 mg tablets
Also known as: Flexeril
sugar pill
Also known as: tolperisone matching placebo
Standard Deviation of Lateral Position (SDLP)
In this crossover study, treatment effects were assessed following initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).
Time frame: at time of peak concentration of drug (Tmax) on Day 1
Standard Deviation of Lateral Position (SDLP) in Simulated Driving Test of Tolperisone Compared to Placebo on Day 2 Next Day Residual Effect
SDLP measured by simulated driving performance of tolperisone compared to placebo on Day 2 prior to morning dosing to determine the next day residual effect or hangover of treatment
Time frame: in the morning predose on Day 2 following nighttime dosing
Sleepiness Endpoint Karolinska Sleepiness Scale KSS
assessment of self-reported motivation for driving performance where 1 equals alert and 9 equals extremely sleepy
Time frame: at Tmax on Day 1
Steady State Standard Deviation of Lateral Position (SDLP) Day 3
SDLP measured on Day 3 at steady state following 3 days of dosing three times per day to achieve steady state drug concentration and effect on outcomes
Time frame: Day 3
| Milestone | ABC (Tolperisone, Cyclobenzaprine, Placebo) | ACB (Tolperisone, Placebo, Cyclobenzaprine) | BAC (Cyclobenzaprine, Tolperisone, Placebo) | BCA (Cyclobenzaprine, Placebo, Tolperisone) | CAB (Placebo, Tolperisone, Cyclobenzaprine) | CBA (Placebo, Cyclobenzaprine, Tolperisone) |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 5 | 6 |
| Completed | 5 | 5 | 5 | 5 | 5 | 6 |
| Not completed | 1 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
In this crossover study, treatment effects were assessed following initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).
| cm of deviation of lateral position | Tolperisone HCl 150 mg | Placebo Oral Tablet | Cyclobenzaprine 10 mg Oral Tablet |
|---|---|---|---|
| Standard Deviation of Lateral Position (SDLP) | 29.3 ± 6.25 | 29.7 ± 6.37 | 38.6 ± 12.35 |
SDLP measured by simulated driving performance of tolperisone compared to placebo on Day 2 prior to morning dosing to determine the next day residual effect or hangover of treatment
| cm of deviation from lateral position | Tolperisone HCl 150 mg | Placebo Oral Tablet | Cyclobenzaprine 10 mg Oral Tablet |
|---|---|---|---|
| Standard Deviation of Lateral Position (SDLP) in Simulated Driving Test of Tolperisone Compared to Placebo on Day 2 Next Day Residual Effect | 29.6 ± 7.08 | 29.9 ± 7.71 | 35.1 ± 10.37 |
assessment of self-reported motivation for driving performance where 1 equals alert and 9 equals extremely sleepy
| units on a scale | Tolperisone HCl 150 mg | Placebo Oral Tablet | Cyclobenzaprine 10 mg Oral Tablet |
|---|---|---|---|
| Sleepiness Endpoint Karolinska Sleepiness Scale KSS | 3.3 ± 1.96 | 3.4 ± 1.99 | 5.6 ± 2.44 |
SDLP measured on Day 3 at steady state following 3 days of dosing three times per day to achieve steady state drug concentration and effect on outcomes
| cm deviation from lateral position | Tolperisone HCl 150 mg | Placebo Oral Tablet | Cyclobenzaprine 10 mg Oral Tablet |
|---|---|---|---|
| Steady State Standard Deviation of Lateral Position (SDLP) Day 3 | 29.8 ± 6.68 | 29.6 ± 7.46 | 31.7 ± 7.9 |
Collected over The total duration of study participation was approximately 4 weeks including screening to follow up.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolperisone HCl 150 mg | 0/33 (0%) | 0/33 (0%) | 15/33 (45.5%) |
| Placebo Oral Tablet | 0/31 (0%) | 0/31 (0%) | 12/31 (38.7%) |
| Cyclobenzaprine 10 mg Oral Tablet | 0/33 (0%) | 0/33 (0%) | 20/33 (60.6%) |
| Event | Tolperisone HCl 150 mg | Placebo Oral Tablet | Cyclobenzaprine 10 mg Oral Tablet |
|---|---|---|---|
| somnolenceNervous system disorders | 5/33 | 2/31 | 10/33 |
| dizzinessNervous system disorders | 1/33 | 2/31 | 3/33 |
| nauseaGastrointestinal disorders | 0/33 | 2/31 | 1/33 |
| headacheNervous system disorders | 2/33 | 0/31 | 0/33 |
| dry mouthGastrointestinal disorders | 0/33 | 0/31 | 2/33 |
| abdominal painGastrointestinal disorders | 1/33 | 1/31 | 1/33 |
| dyspepsiaGastrointestinal disorders | 0/33 | 1/31 | 0/33 |
| upper respiratory infectionInfections and infestations | 0/33 | 1/31 | 0/33 |
| insomniaPsychiatric disorders | 0/33 | 1/31 | 1/33 |
| hyperhydrosisSkin and subcutaneous tissue disorders | 0/33 | 1/31 | 0/33 |
Final analysis on per protocol population (n=33) instead of ITT (n=35) due to 2 subjects being mis-dosed
| Age, Categorical(Participants) | All Study Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 33 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 10 |
| Male | 23 |
| Ethnicity (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| Hispanic or Latino | 10 |
| Not Hispanic or Latino | 23 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 15 |
| White | 17 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| BMI(kg/m2) | All Study Participants |
|---|---|
| Mean | 25.012 ± 2.959 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Dec 2017, 4 months.
Results were first posted in Oct 2020, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine
Neurana Pharmaceuticals, Inc.